Neuralstem Inc. (CUR) Rating Reiterated by Roth Capital
Neuralstem Inc. (NASDAQ:CUR)‘s stock had its “buy” rating restated by analysts at Roth Capital in a research report issued on Thursday. They presently have a $1.20 price objective on the stock. Roth Capital’s price target would indicate a potential upside of 328.72% from the company’s previous close.
Other equities analysts also recently issued reports about the company. Aegis started coverage on Neuralstem in a research report on Monday, November 7th. They set a “buy” rating for the company. Brean Capital initiated coverage on Neuralstem in a report on Tuesday, October 4th. They set a “buy” rating and a $4.00 target price on the stock.
Shares of Neuralstem (NASDAQ:CUR) opened at 0.2799 on Thursday. Neuralstem has a one year low of $0.19 and a one year high of $1.20. The firm’s market cap is $32.12 million. The firm’s 50-day moving average price is $0.29 and its 200-day moving average price is $0.30.
Neuralstem (NASDAQ:CUR) last issued its earnings results on Tuesday, November 8th. The company reported ($0.05) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.03) by $0.02. Neuralstem had a negative net margin of 170,366.66% and a negative return on equity of 4,420.33%. Equities research analysts expect that Neuralstem will post ($0.19) earnings per share for the current fiscal year.
A number of large investors have recently made changes to their positions in the company. Sabby Management LLC purchased a new stake in shares of Neuralstem during the second quarter valued at approximately $1,893,000. Vanguard Group Inc. boosted its stake in shares of Neuralstem by 21.8% in the second quarter. Vanguard Group Inc. now owns 3,384,138 shares of the company’s stock valued at $984,000 after buying an additional 606,500 shares during the last quarter. Finally, Blair William & Co. IL purchased a new stake in shares of Neuralstem during the second quarter valued at approximately $122,000. 18.19% of the stock is currently owned by hedge funds and other institutional investors.
Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.
Receive News & Stock Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related stocks with our FREE daily email newsletter.